New drug cocktail aims to stop kidney cancer comeback
NCT ID NCT05738694
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 3 trial tests whether giving a combination of axitinib (a targeted therapy) and toripalimab (an immunotherapy) before surgery can help prevent kidney cancer from returning in high-risk patients. About 298 participants will either receive the drug combo followed by surgery, or surgery alone. The main goal is to see if the combo improves how long patients stay cancer-free after treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
axitinib plus toripalimab
What this could lead to
If successful, this combination could reduce the risk of kidney cancer returning after surgery, offering a new treatment option for high-risk patients.
What could go wrong
This is an early Phase 3 trial, so results are not yet known. The drugs may cause side effects like high blood pressure or immune reactions, and not all patients may benefit.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Anhui Provincial Hospital
RECRUITINGHefei, China
Contact
-
Cancer Hospital Chinese Academy of Medical Sciences
RECRUITINGBeijing, China
Contact
-
Fudan University Cancer Hospital
RECRUITINGShanghai, China
Contact
-
Peking University First Hospital
RECRUITINGBeijing, China
Contact
-
Sun Yat-sen University Cancer Center
RECRUITINGGuangzhou, China
Contact
-
The First Affiliated Hospital of Zhengzhou Hospital
RECRUITINGZhengzhou, China
Contact
-
Tianjin Medical University Cancer Institute and Hospital
RECRUITINGTianjin, China
Contact
-
West China Hospital
RECRUITINGSichuan, China
Contact